Payment overview · 2025
General Payments
$368.67
18 reported records · 12 companies
Healthcare provider profile · identity verified
Bradley Tymchuk, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HERMISTON, OR · NPI 1437503380
Verified facts
What the public records show
CMS Open Payments records show Bradley Tymchuk, M.D. received $368.67 in general payments during 2025 across 18 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 14.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $52.07 | 14.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $49.77 | 13.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $46.75 | 12.7% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $45.97 | 12.5% | 2 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$30.88 | 8.4% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.88 | 7.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $26.54 | 7.2% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.31 | 5.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.19 | 5.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.05 | 4.9% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.00 | 4.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.26 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $368.67 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $52.07 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.75 | 2 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.97 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.86 | 2 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $30.88 | 2 | 2025 |
Source payment records
|
|||||
| STRENSIQ Normalized: strensiq |
Biological | Alexion Pharmaceuticals, Inc. | $27.88 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $26.54 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $21.31 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.11 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.05 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 106 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
97 | 26 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 39 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
48 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
106 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 450 | 132 |
| Lisinopril | Lisinopril | 311 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 276 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 270 | 81 |
| Gabapentin | Gabapentin | 254 | 75 |
| Losartan Potassium | Losartan Potassium | 223 | 73 |
| Omeprazole | Omeprazole | 207 | 73 |
| Furosemide | Furosemide | 194 | 64 |
| Trazodone Hcl | Trazodone Hcl | 189 | 58 |
| Metformin Hcl | Metformin Hcl | 182 | 56 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 155 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 49 |
| Oxycodone Hcl | Oxycodone Hcl | 148 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 141 | 48 |
| Tramadol Hcl | Tramadol Hcl | 140 | 54 |
| Metoprolol Tartrate | Metoprolol Tartrate | 136 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 46 |
| Allopurinol | Allopurinol | 130 | 38 |
| Montelukast Sodium | Montelukast Sodium | 119 | 40 |
| Eliquis | Apixaban | 110 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 33 |
| Jardiance | Empagliflozin | 106 | 39 |
| Potassium Chloride | Potassium Chloride | 106 | 34 |
| Spironolactone | Spironolactone | 104 | 32 |
| Farxiga | Dapagliflozin Propanediol | 97 | 26 |
| Fentanyl | Fentanyl | 96 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 28 |
| Alprazolam | Alprazolam | 79 | 23 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | 27 |
| Ozempic | Semaglutide | 76 | 15 |
| Pregabalin | Pregabalin | 74 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 20 |
| Atenolol | Atenolol | 71 | 17 |
| Simvastatin | Simvastatin | 67 | 20 |
| Finasteride | Finasteride | 66 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 19 |
| Buspirone Hcl | Buspirone Hcl | 60 | 15 |
| Trulicity | Dulaglutide | 57 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 55 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 54 | 21 |
| Donepezil Hcl | Donepezil Hcl | 53 | 18 |
| Azithromycin | Azithromycin | 52 | 29 |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 14 |
| Methylprednisolone | Methylprednisolone | 48 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | 11 |
| Ezetimibe | Ezetimibe | 47 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 11 |
| Warfarin Sodium | Warfarin Sodium | 44 | 17 |
| Lorazepam | Lorazepam | 43 | 18 |
| Morphine Sulfate Er | Morphine Sulfate | 43 | suppressed |
| Carvedilol | Carvedilol | 42 | 16 |
| Sertraline Hcl | Sertraline Hcl | 42 | 15 |
| Mirtazapine | Mirtazapine | 41 | 19 |
| Ondansetron Odt | Ondansetron | 40 | 16 |
| Meloxicam | Meloxicam | 39 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | suppressed |
| Methocarbamol | Methocarbamol | 37 | 11 |
| Synthroid | Levothyroxine Sodium | 37 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 37 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 20 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Prednisone | Prednisone | 33 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 23 |
| Estradiol | Estradiol | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 31 | suppressed |
| Baclofen | Baclofen | 30 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | 11 |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 13 |
| Topiramate | Topiramate | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Famotidine | Famotidine | 23 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 22 | suppressed |
| Buprenorphine | Buprenorphine | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Oxycontin | Oxycodone Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Pulmicort Flexhaler | Budesonide | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Cartia Xt | Diltiazem Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Symproic | Naldemedine Tosylate | 13 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $368.67 · 18 records | Boehringer Ingelheim Pharmaceuticals, Inc. | GEMTESA, GVOKE HYPOPEN, JARDIANCE, Korlym, MINIMED 780G, MOUNJARO, Ozempic, QULIPTA, RELISTOR, Rybelsus, SHINGRIX, STRENSIQ, UBRELVY, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error